<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315027</url>
  </required_header>
  <id_info>
    <org_study_id>12-005950</org_study_id>
    <secondary_id>R01FD004789</secondary_id>
    <secondary_id>R01NS092625</secondary_id>
    <nct_id>NCT02315027</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Therapy in Multiple System Atrophy</brief_title>
  <official_title>Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether mesenchymal stem cells (MSCs) can be safely&#xD;
      delivered to the cerebrospinal fluid (CSF) of patients with multiple system atrophy (MSA).&#xD;
      Funding Source - FDA OOPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim is to evaluate the safety and tolerability of intrathecal injection of&#xD;
      autologous MSCs in a dose escalation study in patients with MSA. Safety secondary goals&#xD;
      include to monitor changes in peripheral blood and in components of CSF, and monitor for any&#xD;
      changes of nervous system structures using MRI. Efficacy secondary goals include evaluating&#xD;
      potential efficacy by providing a number of studies and instruments that will detect changes&#xD;
      in the course of the disease in terms of autonomic and neurologic symptoms and deficits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event frequency (by severity, type, attribution, and intervention dose).</measure>
    <time_frame>14 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change of Unified Multiple System Atrophy Rating Scale (UMSARS) I score from baseline to 12 months (or last available date), compared with placebo limb of Rifampicin trial (historical control cohort).</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline to 12 months (or last available date) in UMSARS II score.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline to 12 months (or last available date) in UMSARS total score.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in COMPASS-select score from baseline to 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CASS score and thermoregulatory sweat test (TST) % from baseline to 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI morphometric changes using dedicated algorithms to evaluate rate of atrophy of defined areas of brain from baseline to 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF biomarkers from baseline to 2 months.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>MSA</condition>
  <arm_group>
    <arm_group_label>1 dose of 1 × 10(7) MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: Participants will receive a single intrathecal dose of 1 × 10(7) mesenchymal stem cells (MSCs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses of 5 × 10(7) MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: Participants will receive one intrathecal dose of 5 × 10(7) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 5 × 10(7) MSCs approximately one month later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses of 1 × 10(8) MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3: Participants will receive one intrathecal dose of 1 × 10(8) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 1 × 10(8) MSCs approximately one month later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 doses of 5 x 10(7) (±20%) MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4: Participants will receive up to 10 doses of 5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 doses of 2.5 x 10(7) (±20%) MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5: Participants will receive up to 10 doses of 2.5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Mesenchymal Stem Cells</intervention_name>
    <description>single dose of 1 × 10(7) cells intrathecally</description>
    <arm_group_label>1 dose of 1 × 10(7) MSCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Mesenchymal Stem Cells</intervention_name>
    <description>2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart</description>
    <arm_group_label>2 doses of 5 × 10(7) MSCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Mesenchymal Stem Cells</intervention_name>
    <description>2 doses of 1 × 10(8) cells intrathecally each 1 month apart</description>
    <arm_group_label>2 doses of 1 × 10(8) MSCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Mesenchymal Stem Cells</intervention_name>
    <description>Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart</description>
    <arm_group_label>10 doses of 5 x 10(7) (±20%) MSCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Mesenchymal Stem Cells</intervention_name>
    <description>Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart</description>
    <arm_group_label>10 doses of 2.5 x 10(7) (±20%) MSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Participants aged 30-80 years old with a diagnosis of MSA based on clinical criteria&#xD;
             and standardized autonomic testing. This approach allows for identification of&#xD;
             patients with MSA with very high specificity and is yet sensitive enough to allow for&#xD;
             enrollment of patients at a disease stage at which an intervention on the natural&#xD;
             disease course has a meaningful impact on patient outcome. Patients therefore have to&#xD;
             fulfill Gilman Criteria (2000) for probable MSA of the parkinsonian subtype (MSA-P) or&#xD;
             cerebellar subtype (MSA-C) and have findings on autonomic function testing suggestive&#xD;
             of MSA (CASS ≥5 or a TST% ≥25%).&#xD;
&#xD;
          2. Participants who are less than 4 years from the time of documented MSA diagnosis.&#xD;
&#xD;
          3. Participants with an anticipated survival of at least 3 years in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          4. Participants who are willing and able to give informed consent.&#xD;
&#xD;
          5. &quot;Normal&quot; cognition as assessed by Mini-Mental State Examination (MMSE). We will&#xD;
             require a value &gt;24.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Any of the following conditions will exclude the participant from entering the study:&#xD;
&#xD;
          1. Women of childbearing potential who do not practice an acceptable method of birth&#xD;
             control. Acceptable methods of birth control in this study are: surgical&#xD;
             sterilization, intrauterine devices, partner's vasectomy, a double-protection method&#xD;
             (condom or diaphragm with spermicide), hormonal contraceptive drug (i.e., oral&#xD;
             contraceptive, contraceptive patch, long-acting injectable contraceptive) with a&#xD;
             required second mode of contraception.&#xD;
&#xD;
          2. Participants with a clinically significant or unstable medical or surgical condition&#xD;
             that, in the opinion of the investigator, might preclude safe completion of the study&#xD;
             or might affect the results of the study. These include conditions causing significant&#xD;
             central nervous system (CNS) or autonomic dysfunction, including congestive heart&#xD;
             failure, recent (&lt;6 months) myocardial infarct, cardiopulmonary disease, severe,&#xD;
             uncontrolled hypertension, thrombocytopenia (&lt;50 x 10(9)/L), severe anemia (&lt;8g/dl),&#xD;
             immunocompromised state, liver or kidney disease (creatinine &gt;2.3mg/dl), uncontrolled&#xD;
             diabetes mellitus (HbA1c &gt;10g%), alcoholism, amyloidosis, uncontrolled hypothyroidism,&#xD;
             sympathectomy, unstable peripheral neuropathies, concurrent infections, orthopedic&#xD;
             problems that compromise mobility and activity of daily living, cerebrovascular&#xD;
             accidents, neurotoxin or neuroactive drug exposure, parkinsonism due to drugs&#xD;
             (including neuroleptics, alpha-methyldopa, reserpine, metoclopramide).&#xD;
&#xD;
          3. Participants with malignant neoplasms.&#xD;
&#xD;
          4. Participants who have taken any investigational products within 60 days prior to&#xD;
             baseline.&#xD;
&#xD;
          5. Medications that could affect autonomic function. If patients are taking those&#xD;
             medications, those will be suspended prior to autonomic testing. Therapy with&#xD;
             midodrine, anticholinergic, alpha and beta adrenergic antagonists or other medications&#xD;
             that affect autonomic function will be withdrawn 48 hours prior to autonomic&#xD;
             evaluations. Fludrocortisone doses up to 0.2 mg per day will be permitted.&#xD;
&#xD;
          6. Diseases with features of Parkinsons Disease; e.g., diffuse Lewy body disease,&#xD;
             progressive supranuclear palsy, essential tremor, hereditary olivopontocerebellar&#xD;
             atrophy, or postencephalitic parkinsonism.&#xD;
&#xD;
          7. Dementia (DSM-IV criteria - American Psychiatric Association 1994). The score on the&#xD;
             Mini-Mental State Examination must be &gt;24.&#xD;
&#xD;
          8. History of electroconvulsive therapy.&#xD;
&#xD;
          9. History of brain surgery for Parkinsons disease.&#xD;
&#xD;
         10. Patients with contraindication for MRI scanning, including those with MRI-incompatible&#xD;
             pacemakers&#xD;
&#xD;
         11. Patients with active systemic infection or local infection, which is close to the&#xD;
             spinal injection site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Singer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phillip Low, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Wolfgang Singer</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

